Physician profile
Anil Piya
NPI 1841446408
$13,972.42
in general payments reported to CMS, 2019-2025
31 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $4,578 · 2021: $768 · 2022: $5,377 · 2023: $530 · 2024: $1,142 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $4,483.67 | 2019-2021 | |
| Mannkind Corporation | $3,504.59 | 2021-2024 | |
| Ascendis Pharma Endocrinology INC | $1,040.97 | 2022-2025 | Skytrofa |
| Tolmar Pharmaceuticals, INC. | $698.06 | 2022 | |
| Novo Nordisk INC | $603.23 | 2019-2025 | Sogroya, Rybelsus, Ozempic |
| Abbvie INC. | $418.34 | 2019-2025 | |
| Insulet Corporation | $412.27 | 2019-2024 | Omnipod |
| Alexion Pharmaceuticals, INC. | $316.77 | 2019-2024 | Strensiq |
| Azurity Pharmaceuticals, INC. | $240.83 | 2023-2025 | Triptodur, Triptodur |
| Ultragenyx Pharmaceutical INC. | $236.90 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $218.13 | 2020-2023 | Gvoke Hypopen |
| Pfizer INC. | $208.22 | 2019-2024 | |
| Medtronic, INC. | $186.41 | 2021-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $154.16 | 2023-2025 | |
| Rhythm Pharmaceuticals, INC. | $149.05 | 2022-2025 | Imcivree, Imcivree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $122.50 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Dexcom, INC. | $117.07 | 2019-2021 | |
| Tolmar, INC. | $105.01 | 2024-2025 | Fensolvi |
| Zealand Pharma US, INC. | $94.35 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $92.60 | 2019 | |
| Eton Pharmaceuticals, INC. | $82.76 | 2023-2025 | Alkindi, Increlex, Khindivi |
| Tandem Diabetes Care, INC. | $82.05 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $76.95 | 2021-2023 | Freestyle Libre |
| Vistapharm, INC. | $76.51 | 2021 | |
| Kyowa Kirin, INC. | $50.52 | 2023-2025 | Crysvita |
| Endo Pharmaceuticals INC. | $47.59 | 2019-2021 | |
| Biomarin Pharmaceutical INC. | $46.77 | 2022-2024 | Voxzogo 1.2mg |
| Astrazeneca Pharmaceuticals LP | $40.11 | 2021 | |
| Lilly USA, LLC | $27.97 | 2022-2023 | Baqsimi |
| Sandoz INC. | $21.65 | 2021 | |
| Ibsa Pharma INC. | $16.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Piya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.